The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation: a meta-analysis
- 1 October 2003
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 32 (8) , 771-775
- https://doi.org/10.1038/sj.bmt.1704228
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantationBone Marrow Transplantation, 2001
- Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantationBone Marrow Transplantation, 2000
- Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factorBone Marrow Transplantation, 2000
- Pathogenesis of Acute Graft-Versus-Host Disease: Cytokines and Cellular EffectorsJournal of Hematotherapy & Stem Cell Research, 2000
- Influence of recombinant human granulocyte colony-stimulating factor (filgrastim) on hematopoietic recovery and outcome following allogeneic bone marrow transplantation (BMT) from volunteer unrelated donorsBone Marrow Transplantation, 1999
- Th2 cytokines (IL‐4, IL‐10 and IL‐13) and IL‐12 mRNA expression by concanavalin A‐stimulated peripheral blood mononuclear cells during chronic graft‐versus‐host diseaseEuropean Journal of Haematology, 1996
- Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in childrenMedical and Pediatric Oncology, 1996
- Placebo-controlled phase III trial of lenograstim in bone-marrow transplantationThe Lancet, 1994
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor (rGM-CSF)Drugs, 1992
- Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trialThe Lancet, 1990